Lactoferrin inhibits E. coli O157:H7 growth and attachment to intestinal epithelial cells

Veterinarni Medicina

Volumn 55, Issue 8, 2010, Pages 359-368

  Yekta, Maryam Atef ^a   Verdonck, F ^a   Van Den Broeck, W ^a   Goddeeris, B M ^a,b   Cox, E ^a   Vanrompay, D ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

EspA; EspB; Transferring; Type III secretion system

Indexed keywords

BACTERIA (MICROORGANISMS); BOS; BOVINAE; ESCHERICHIA COLI;

EID: 77957069441     PISSN: 03758427     EISSN: None     Source Type: Journal    
DOI: 10.17221/2954-VETMED     Document Type: Article

References (42)

1. Aguila A, Herrera AG, Morrison D, Cosgrove B, Perojo A, Montesinos I, Perez J, Sierra G, Gemmell CG, Brock JH (2001): Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. Fems Immunology and Medical Microbiology 31, 145-152
2. Al-Nabulsi AA, Holley RA (2007): Effects on Escherichia coli O157:H7 and meat starter cultures of bovine lactoferrin in broth and microencapsulated lactoferrin in dry sausage batters. International Journal of Food Microbiology 113, 84-91
3. Baker EN, Baker HM (2005): Molecular structure, binding properties and dynamics of lactoferrin. Cellular and Molecular Life Sciences 62, 2531-2539
4. Baker EN, Baker HM (2009): A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91, 3-10
5. Bavaro MF (2009): Escherichia coli O157: what every internist and gastroenterologist should know. Current Gastroenterology Reports 11, 301-306
6. Beeckman DSA, Van Droogenbroeck C, De Cock BJA, Van Oostveldt P, Vanrompay DCG (2007): Effect of ovotransferrin and lactoferrins on Chlamydophila psittaci adhesion and invasion in HD11 chicken macrophages. Veterinary Research 38, 729-739
7. Callaway TR, Carr MA, Edrington TS, Anderson RC, Nisbet DJ (2009): Diet, Escherichia coli O157:H7, and cattle: a review after 10 years. Current Issues in Molecular Biology 11, 67-79
8. Chapple DS, Hussain R, Joannou CL, Hancock REW, Odell E, Evans RW, Siligardi G (2004): Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrobial Agents and Chemotherapy 48, 2190-2198
9. Cookson AL, Woodward MJ (2003): The role of intimin in the adherence of enterohaemorrhagic Escherichia coli (EHEC) O157:H7 to HEp-2 tissue culture cells and to bovine gut explant tissues. International Journal of Medical Microbiology 292, 547-553
10. Dibb-Fuller MP, Best A, Stagg DA, Cooley WA, Woodward MJ (2001): An in-vitro model for studying the interaction of Escherichia coli O157: H7 and other enteropathogens with bovine primary cell cultures. Journal of Medical Microbiology 50, 759-769
11. Dundas S, Todd WTA, Neill MA, Tarr PI (2005): Using antibiotics in suspected haemolytic-uraemic syndrome-Antibiotics should not be used in Escherichia coli O157:H7 infection. British Medical Journal 330, 1209-1209
12. Ellison RT, Giehl TJ (1991): Killing of Gram negative bacteria by lactoferrin and lysozyme. Journal of Clinical Investigation 88, 1080-1091
13. Ellison RT, Giehl TJ, Laforce FM (1988): Damage of theouter membrane of enteric Gram negative bacteria by lactoferrin and transferrin. Infection and Immunity 56, 2774-2781
14. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K (1988): Site of action of a vero toxin (VT2) from Escherichia coli O157:H7 and of shiga toxin on eukaryotic ribosomes RNA N-glycosidase activity of the toxins.European Journal of Biochemistry 171, 45-50
15. Fincher LM, Parker CD, Chauret CP (2009): Occurrence and Antibiotic Resistance of Escherichia coli O157:H7 in a Watershed in North-Central Indiana. Journal of Environmental Quality 38, 997-1004
16. Frankel G, Phillips AD, Rosenshine I, Dougan G, Kaper JB, Knutton S (1998): Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Molecular Microbiology 30, 911-921
17. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG (2003): Human lactoferrin impairs virulence of Shigella flexneri. Journal of Infectious Diseases 187, 87-95
18. Groenink J, Walgreen-Weterings E, van't Hof W, Veerman ECI, Amerongen AVN (1999): Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiology Letters 179, 217-222
19. Haney EF, Nazmi K, Lau F, Bolscher JG, Vogel H J (2009): Novel lactoferrampin antimicrobial peptides derived from human lactoferrin. Biochimie 91, 141-154
20. Izumikawa K, Hirakata Y, Yamaguchi T, Takemura H, Maesaki S, Tomono K, Igimi S, Kaku M, Yamada Y, Kohno S, Kamihira S (1998): Escherichia coli O157 interactions with human intestinal Caco-2 cells and the influence of fosfomycin. Journal of Antimicrobial Chemotherapy 42, 341-347
21. Jenny M, Pedersen N, Hidayat BJ, Schennach H, Fuchs D (2010): Bovine colostrum modulates immune activation cascades in human peripheral blood mononuclear cells in vitro. New Microbiologica 33, 129-135
22. Jerse AE, Yu J, Tall BD, Kaper JB (1990): A genetic locus of eneropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proceedings of the National Academy of Sciences of the United States of America 87, 7839-7843
23. Karpman D, Bekassy ZD, Sjogren A C, Dubois MS, Karmali MA, Mascarenhas M, Jarvis KG, Gansheroff LJ, O'Brien AD, Arbus GS, Kaper JB (2002): Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatric Nephrology 17, 201-211
24. Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, Tsukiji M, Fujimura R, Muranaka Y, Isihida H (2000): Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic Escherichia coli to host cells. Bioscience Biotechnology and Biochemistry 64, 348-354
25. Mosmann T (1983): Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 16, 55-63
26. Naidu SS, Erdei J, Czirok E, Kalfas S, Gado I, Thoren A, Forsgren A, Naidu AS (1991): Specific binding of lactoferrin to Escherichia coli isolated from human intestinal infections. Apmis 99, 1142-1150
27. Nataro JP, Kaper JB (1998): Diarrheagenic Escherichia coli. Clinical Microbiology Reviews 11, 142-201
28. Ochoa TJ, Cleary TG (2009): Effect of lactoferrin on enteric pathogens. Biochimie 91, 30-34
29. Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG (2003): Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infection and Immunity 71, 5149-5155
30. Orsi N (2004): The antimicrobial activity of lactoferrin: Current status and perspectives. Biometals 17, 189-196
31. Panos GZ, Betsi GI, Falagas ME (2006): Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Alimentary Pharmacology & Therapeutics 24, 731-742
32. Safdar N, Said A, Gangnon RE, Maki DG (2002): Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 enteritis-A meta-analysis. Jama-Journal of the American Medical Association 288, 996-1001
33. Schroeder CM, Zhao CW, DebRoy C, Torcolini J, Zhao SH, White DG, Wagner DD, McDermott PF, Walker RD, Meng JH (2002): Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Applied and Environmental Microbiology 68, 576-581
34. Senkovich O, Cook WJ, Mirza S, Hollingshead SK, Protasevich II, Briles DE, Chattopadhyay D (2007): Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein A provides insight into microbial defense mechanism. Journal of Molecular Biology 370, 701-713
35. Shimazaki K, Uji K, Tazume T, Kumura H, Shimo-Oka T (2000): Approach to identification and comparison of the heparin-interacting sites of lactoferrin using synthetic peptides. Lactoferrin: Structure, Function and Applications 1195, 37-46
36. Shin K, Wakabayashi H, Yamauchi K, Yaeshima T, Iwatsuki K (2008): Recombinant human intelectin binds bovine lactoferrin and its peptides. Biological & Pharmaceutical Bulletin 31, 1605-1608
37. Tsuda H, Kozu T, Iinuma G, Ohashi Y, Saito Y, Saito D, Akasu T, Alexander D B, Futakuchi M, Fukamachi K, Xu JG, Kakizoe T, Iigo M (2010): Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 23, 399-409
38. Van der Kraan MIA, Van Marle J, Nazmi K, Groenink J, Van't Hof W, Veerman ECI, Bolscher J GM, Arnerongen AVN (2005): Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 26, 1537-1542
39. Vandekerckhove A, Glorieux S, Van den Broeck W, Gryspeerdt A, Van der Meulen KM, Nauwynck HJ (2009): In vitro culture of equine respiratory mucosa explants. Veterinary Journal 181, 280-287
40. Vilte DA, Larzabal M, Cataldi AA, Mercado EC (2008): Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli. Clinical and Vaccine Immunology 15, 1208-1213
41. Vorland LH, Ulvatne H, Andersen J, Haukland HH, Rekdal O, Svendsen JS, Gutteberg TJ (1998): Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scandinavian Journal of Infectious Diseases 30, 513-517
42. Xu XX, Jiang HR, Li HB, Zhang TN, Zhou Q, Liu N (2010): Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. Journal of Dairy Science 93, 2344-2350